Literature DB >> 10373718

Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.

M T Roe1, D J Moliterno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10373718     DOI： 10.1023/a:1008927025962

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  36 in total

1.  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Authors:  E J Topol; J J Ferguson; H F Weisman; J E Tcheng; S G Ellis; N S Kleiman; R J Ivanhoe; A L Wang; D P Miller; K M Anderson; R M Califf
Journal:  JAMA       Date:  1997-08-13       Impact factor: 56.272

2.  Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.

Authors:  D A Vorchheimer; V Fuster
Journal:  Circulation       Date:  1998-02-03       Impact factor: 29.690

Review 3.  Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.

Authors:  E J Topol
Journal:  Circulation       Date:  1998-01-20       Impact factor: 29.690

4.  Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.

Authors:  T H Müller; H Weisenberger; R Brickl; H Narjes; F Himmelsbach; J Krause
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

5.  Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.

Authors:  C P Cannon; C H McCabe; S Borzak; T D Henry; M D Tischler; H S Mueller; R Feldman; S T Palmeri; K Ault; S A Hamilton; J M Rothman; W F Novotny; E Braunwald
Journal:  Circulation       Date:  1998-02-03       Impact factor: 29.690

6.  Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty.

Authors:  S G Ellis; G S Roubin; S B King; J S Douglas; W S Weintraub; R G Thomas; W R Cox
Journal:  Circulation       Date:  1988-02       Impact factor: 29.690

Review 7.  Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy.

Authors:  B S Coller
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

8.  Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile.

Authors:  A M Lincoff; J J Popma; S G Ellis; J A Hacker; E J Topol
Journal:  J Am Coll Cardiol       Date:  1992-04       Impact factor: 24.094

9.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.